I am thrilled to announce that BrightInsight has been named to Newsweek’s 2024 list of The World’s Best Digital Health Companies. This award comes on the heels of BrightInsight being named to Forbes 2024 List of America’s Best Startup Employers earlier this month.
Being recognized as one of Newsweek’s World’s Best Digital Health Companies 2024 is a testament to the dedication of our team to develop our best-in-class SaaS platform, drive meaningful awareness and engagement in the market, and ultimately demonstrate healthy financial performance.
The prestigious World’s Best Digital Health Companies 2024 ranking lists the top 400 companies from over 35 different countries. The winners were ranked across seven market segments: Data Analytics, Diagnostics, Health Records, Medical Management, Prevention, Telehealth and Treatment. The top list is based on three key pillars:
- Financial Performance: Statista analyzed financial data from publicly available sources such as annual reports, company websites, media outlets, and databases. Companies also had the opportunity to submit data using an online application form, accessible via Newsweek.com.
- Impact: Statista cooperated with data and market intelligence company HolonIQ to assess a company in different impact dimensions, encompassing factors such as the quality and uniqueness of their product/service, as well as the expertise of their leadership team.
- Online Engagement: Statista analyzed traffic data from company websites and apps to assess the engagement of users with their product/service.
As reinforced by this Newsweek award, BrightInsight has excelled across these three categories since its inception:
- Financial Performance: BrightInsight made the 2023 Deloitte Technology Fast 500™ list for the second year in row. Winners were selected based on percentage fiscal year revenue growth from 2019 to 2022, with BrightInsight ranking at number 307 with 431% revenue growth.
- Impact: The company has invested heavily in its technology to deliver industry-leading scalability, functionality, configurability, speed, compliance and global availability. The BrightInsight Platform now includes new mobile capabilities which enable our biopharma customers to rapidly build, configure, localize and optimize patient companion apps at scale, in a more cost-effective manner. BrightInsight’s out-of-the-box data dashboards enable biopharma companies to export and analyze app utilization and engagement for ongoing app optimization, in a way that meets stringent privacy requirements.
- Online Engagement: BrightInsight has been recognized year over year with multiple awards from leading organizations including Forbes, Frost & Sullivan, CB Insights, Deloitte and others. Our global thought leadership program and social media communities continue to grow and see engagement rates that are double the industry average.
During a period of time where many digital health companies have fallen to the wayside and are under increasing pressure to demonstrate clear ROI of their solutions, this latest recognition underscores BrightInsight’s value proposition for biopharma companies pursuing digital initiatives to improve the patient experience and outcomes.
I’m very proud of our team and what we have built.
